TNF and neoplasm: Marked and dose-dependent increases of iNOS and TNF-α immunoreactivities were demonstrated in all platycodin D treated mice as compared with tumor-bearing mice, but gemcitabine 160 mg/kg did not influenced on the iNOS and TNF-α immunoreactivities in tumor masses (Table 4, Figure 8).